UDK: 615.036.8:616-005.6

COST-EFFECTIVENESS OF NEW ORAL ANTICOAGULANTS IN THE TREATMENT OF DEEP VEIN THROMBOSIS

O. V. Shatalova, O. N. Smuseva, V. S. Gorbatenko, A. S. Maslakov

Волгоградский государственный медицинский университет, кафедра клинической фармакологии и интенсивной терапии

Abstract

The results of a pharmacoeconomic study of treating deep vein thrombosis in an inpatient setting are presented in the article. The authors have demonstrated that the use of rivaroxaban results in cost savings of 2959.66–4431.72 roubles per patient for the treatment of DVT. Irrespective of price fluctuations in DVT medicines, the use of rivaroxaban for treating DVT in an inpatient setting seems to be beneficial.

Keywords

cost-effectiveness, new oral anticoagulants, rivaroxaban, dabigatran, deep vein thrombosis (DTV).

Contacts

Шаталова Ольга Викторовна — к. м. н., докторант кафедры клинической фармакологии и интенсивной терапии, Волгоградский государственный медицинский университет, email: shov_med@mail.ru